Axalbion SA is a clinical-stage biopharmaceutical company developing TRPM8 agonists. Its lead candidate AX-8 is being developed for topical treatment of refractory chronic cough and dry eye syndrome.
AI-generated
Offering
Products & services
Industry:Research & DevelopmentPharmaceutical Industry
Outbound Leads by COHAGA
Looking for direct email addresses and phone numbers?
Leadhub delivers verified contact details and decision-makers from over 750,000 Swiss companies — management, procurement, marketing, HR.
Clinical programme for local therapy with a TRPM8 agonist for refractory chronic cough, with a topical formulation intended to reduce cough hypersensitivity and limit systemic exposure.
Comparisons
Axalbion SA in comparison
Soon
Industry comparisons are coming soon
We're preparing industry comparisons that rank Axalbion SA by reviews, experience and specialisations.
Knowledge
No knowledge articles yet
Once Axalbion SA has claimed this profile, we'll publish editorial articles and case studies here together.